Myriad Genetics

About: Myriad Genetics is a company organization based out in Munich, Germany. It is known for research contribution in the topics: Cancer & Breast cancer. The organization has 562 authors who have published 586 publications receiving 56046 citations. The organization is also known as: Myriad Genetics, Inc..

Markov chain Monte Carlo methods for family trees using a parallel processor

Abstract: A 1024 CPU parallel computer is used to obtain simulated genotypes in the Tristan da Cunha pedigree using random local updating methods. A four-colour theorem is invoked to justify simultaneous updating. Multiple copies of the program are run simultaneously. These results are used to infer the source of the B allele of the ABO blood group that is present in the population.

Pharmaceutical compositions and use thereof

Abstract: The present invention relates to pharmaceutical compositions and dosage compositions of compounds, including injectable formulations for the parenteral delivery of such compounds into patients in need of such treatment. Also featured are methods of making and using the compositions, including methods for the treatment of neoplastic diseases.

Identification of biomarkers to predict response to single-agent platinum chemotherapy in metastatic triple-negative breast cancer (mTNBC): Correlative studies from TBCRC009.

Abstract: 1020 Background: TNBC has a poor prognosis compared to other BC subtypes and lacks therapeutic targets. We previously reported TBCRC009, a multicenter single-arm phase II study of single-agent plat...

Specific mutations of map kinase 4 (MKK4) in human tumor cell lines identify it as a tumor suppressor in various types of cancer

Abstract: The present invention relates to mutations in the MKK4 gene in human cancers and their use in the diagnosis and prognosis of human cancer. Specific mutations in the MKK4 gene which are associated with breast, pancreatic, colorectal and testicular cancers have been identified. The invention also relates to the therapy of human cancers which have a mutation in the MKK4 gene, including gene therapy, protein replacement therapy and protein mimetics. Finally, the invention relates to the screening of drugs for cancer therapy.

Gene variants and use thereof

Abstract: Variants in TLK1, WARS2, ARTS2, MSR, AKAP9, DNAJD1, GOLPH4, RABEP1, TAP2, NARG2, DDX58, CD39, FKBP1a, SRI, XRRA1, IRF5 and AMFR genes are disclosed which are useful as biomarkers for predicting the TLK1, WARS2, ARTS2, MSR, AKAP9, DNAJD1, GOLPH4, RABEP1, TAP2, NARG2, DDX58, CD39, FKBP1a, SRI, XRRA1, IRF5 or AMFR gene expression level and the biological functions associated thereof.